Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
Inventors
Cai, Xiong • Zhai, Haixaio • Lai, Chengjung • Qian, Changgeng
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
Core Innovation
The disclosure is directed to compounds represented by formula (XIV) and formula XXII, or pharmaceutically acceptable salts or prodrugs thereof, with structural variables constrained to specific allowable values. The defined chemical space includes selected substituent sets for n, p, G1, G2, R1, R2, R8, R10, and additional variables including t, v, w, u, d, e, B, C, G4, G5, G6, G7, R33, and R100, together with compounds selected from Table A and related structure depictions.
The structures are described as thieno[3,2-d]pyrimidine derivatives and N-hydroxy carboxamide compounds with fused heteroaromatic scaffolds and varied substituents on the core. The disclosed subject matter includes preferred and allowable substituent structures such as aryl, heteroaryl, heterocyclic, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF3, CN, NO2, sulfonyl, acyl, carboxamide, and carboxylic acid motifs, as well as pharmaceutical composition forms containing the claimed compounds with a pharmaceutically acceptable carrier.
The document further describes zinc-binding inhibitors directed to phosphoinositide 3-kinase (PI3K), including compounds within structural scopes such as deazapurines, thienopyrimidines, and furopyrimidines. The compounds are described as capable of inhibiting PI3K and, in some cases, acting as inhibitors of histone deacetylase (HDAC) and sometimes matrix metalloproteinase (MMP), with downstream pathway disruption and p53/p21-mediated apoptosis and cell-cycle arrest described in the summary.
Claims Coverage
The independent claim set includes formula-based compound claims for formula (XIV) and formula XXII, together with a selection claim directed to compounds delineated in Table A. Across these independent claims, the inventive features are constrained chemical scaffolds and explicit table-based selection, with optional pharmaceutically acceptable salts or prodrugs and dependent claims that add pharmaceutical composition context and, in some items, treatment-use context.
Formula (XIV) compound definition
A compound represented by formula (XIV), or a pharmaceutically acceptable salt or prodrug thereof, with constrained variables including n, p, G1, G2, R8, R1, R2, R10, B, d, e, C, R100, and R33.
Formula XXII compound definition
A compound represented by formula XXII, or a pharmaceutically acceptable salt or prodrug thereof, with constrained variables including n, p, G1, G2, R8, R1, R2, R10, t, v, w, u, G4, G5, G6, G7, R5, and R6.
Selection of Table A compounds
A compound selected from the compounds delineated in Table A, or a pharmaceutically acceptable salt, or prodrug thereof.
Overall, the claim coverage defines specific compound families through formula (XIV) and formula XXII with multiple substituent and ring-variable constraints, and also covers compounds selected from Table A. The claims further extend to pharmaceutically acceptable salts or prodrugs, with dependent claims adding pharmaceutical composition elements and, in some items, treatment-use context.
Stated Advantages
Treat or prevent cancers, including hematologic cancers.
Reduce circulating lymphocytes (reversible lymphopenia).
Treat immune-mediated disorders.
Potential synergistic effects compared to separate drug combinations.
The multi-target agents can overcome resistance associated with PI3K single-agent inhibition.
The summary describes downstream pathway disruption including PI3K-AKT-mTOR and RAF-MEK-ERK pathways and receptor tyrosine kinase (RTK) downregulation.
The summary associates the inhibition with p53/p21-mediated apoptosis and cell-cycle arrest.
Compounds are evaluated for inhibitory activity against PI3K isoforms, as well as HDAC inhibitory activity and mTOR kinase activity.
Biological evaluation includes IC50 grading and antiproliferative activity across multiple cancer cell lines.
Inhibitory activity toward PI3 kinase and HDAC is stated as significant.
The compounds may also inhibit mTOR.
Documented Applications
Administering the compounds to treat or prevent cancers, including hematologic cancers.
Reducing circulating lymphocytes, described as reversible lymphopenia.
Treating immune-mediated disorders.
Use in combination therapy with kinase modulators and other treatment modalities is discussed in the document.
Inhibiting PI3 kinase by contacting PI3K with an effective inhibitory amount of a Formula I compound [procedural detail omitted for safety].
Treating a PI3K-related disease or disorder by administering a therapeutically effective amount of a pharmaceutical composition described in a dependent claim [procedural detail omitted for safety].
The compounds are intended for multi-target inhibition including PI3K, and are also described as HDAC inhibitors and sometimes MMP inhibitors through zinc binding, in the context of downstream pathway disruption and cancer-related effects.
Use in relation to measuring and characterizing PI3Kα/β/δ/γ IC50 activity, HDAC inhibitory activity, and mTOR kinase activity.
Antiproliferative activity and cell proliferation assays across multiple cancer cell lines.
Pharmaceutical composition use cases are described for including the claimed compound as an active ingredient with a pharmaceutically acceptable carrier.
The patent states biological relevance in terms of significant inhibitory activity toward PI3 kinase and HDAC, and may also inhibit mTOR.
Interested in licensing this patent?